|
1
|
Drakopanagiotakis F, Krauss E, Michailidou
I, Drosos V, Anevlavis S, Günther A and Steiropoulos P: Lung cancer
and interstitial lung diseases. Cancers (Basel).
16(2837)2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hubbard R, Venn A, Lewis S and Britton J:
Lung cancer and cryptogenic fibrosing alveolitis. A
population-based cohort study. Am J Respir Crit Care Med. 161:5–8.
2000.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Harris JM, Johnston ID, Rudd R, Taylor AJ
and Cullinan P: Cryptogenic fibrosing alveolitis and lung cancer:
The BTS study. Thorax. 65:70–76. 2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Iwata T, Yoshida S, Nagato K, Nakajima T,
Suzuki H, Tagawa T, Mizobuchi T, Ota S, Nakatani Y and Yoshino I:
Experience with perioperative pirfenidone for lung cancer surgery
in patients with idiopathic pulmonary fibrosis. Surg Today.
45:1263–1270. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Saito Y, Kawai Y, Takahashi N, Ikeya T,
Murai K, Kawabata Y and Hoshi E: Survival after surgery for
pathologic stage IA non-small cell lung cancer associated with
idiopathic pulmonary fibrosis. Ann Thorac Surg. 92:1812–1817.
2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Watanabe A, Higami T, Ohori S, Koyanagi T,
Nakashima S and Mawatari T: Is lung cancer resection indicated in
patients with idiopathic pulmonary fibrosis? J Thorac Cardiovasc
Surg. 136:1357–1363. 2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Watanabe N, Taniguchi H, Kondoh Y, Kimura
T, Kataoka K, Nishiyama O, Kondo M and Hasegawa Y: Efficacy of
chemotherapy for advanced nonsmall cell lung cancer with idiopathic
pulmonary fibrosis. Respiration. 85:326–331. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Fukui M and Suzuki K, Ando K, Matsunaga T,
Hattori A, Takamochi K, Nojiri S and Suzuki K: Survival after
surgery for clinical stage I non-small-cell lung cancer with
interstitial pneumonia. Lung Cancer. 165:108–114. 2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sato T, Teramukai S, Kondo H, Watanabe A,
Ebina M, Kishi K, Fujii Y, Mitsudomi T, Yoshimura M, Maniwa T, et
al: Impact and predictors of acute exacerbation of interstitial
lung diseases after pulmonary resection for lung cancer. J Thorac
Cardiovasc Surg. 147:1604–1611.e3. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sekihara K, Aokage K, Miyoshi T, Tane K,
Ishii G and Tsuboi M: Perioperative pirfenidone treatment as
prophylaxis against acute exacerbation of idiopathic pulmonary
fibrosis: A single-center analysis. Surg Today. 50:905–911.
2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Behr J, Prasse A, Kreuter M, Johow J, Rabe
KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, et al:
Pirfenidone in patients with progressive fibrotic interstitial lung
diseases other than idiopathic pulmonary fibrosis (RELIEF): A
double-blind, randomised, placebo-controlled, phase 2b trial.
Lancet Respir Med. 9:476–486. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Maher TM, Corte TJ, Fischer A, Kreuter M,
Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K,
Gilberg F and Cottin V: Pirfenidone in patients with unclassifiable
progressive fibrosing interstitial lung disease: A double-blind,
randomised, placebo-controlled, phase 2 trial. Lancet Respir Med.
8:147–157. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Flaherty KR, Wells AU, Cottin V, Devaraj
A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S,
et al: Nintedanib in progressive fibrosing interstitial lung
diseases. N Engl J Med. 381:1718–1727. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Distler O, Highland KB, Gahlemann M, Azuma
A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, et
al: Nintedanib for systemic sclerosis-associated interstitial lung
disease. N Engl J Med. 380:2518–2528. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Richeldi L, Costabel U, Selman M, Kim DS,
Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G,
et al: Efficacy of a tyrosine kinase inhibitor in idiopathic
pulmonary fibrosis. N Engl J Med. 365:1079–1087. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Richeldi L, du Bois RM, Raghu G, Azuma A,
Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y,
et al: Efficacy and safety of nintedanib in idiopathic pulmonary
fibrosis. N Engl J Med. 370:2071–2082. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe
S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al:
Double-blind, placebo-controlled trial of pirfenidone in patients
with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.
171:1040–1047. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Taniguchi H, Ebina M, Kondoh Y, Ogura T,
Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, et al:
Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J.
35:821–829. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Noble PW, Albera C, Bradford WZ, Costabel
U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA,
Szwarcberg J, et al: Pirfenidone in patients with idiopathic
pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet.
377:1760–1769. 2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Huang H, Dai HP, Kang J, Chen BY, Sun TY
and Xu ZJ: Double-blind randomized trial of pirfenidone in chinese
idiopathic pulmonary fibrosis patients. Medicine (Baltimore).
94(e1600)2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
King TE Jr, Bradford WZ, Castro-Bernardini
S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM,
Kardatzke D, Lancaster L, et al: A phase 3 trial of pirfenidone in
patients with idiopathic pulmonary fibrosis. N Engl J Med.
370:2083–2092. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Iwata T, Yoshino I, Yoshida S, Ikeda N,
Tsuboi M, Asato Y, Katakami N, Sakamoto K, Yamashita Y, Okami J, et
al: A phase II trial evaluating the efficacy and safety of
perioperative pirfenidone for prevention of acute exacerbation of
idiopathic pulmonary fibrosis in lung cancer patients undergoing
pulmonary resection: West Japan oncology group 6711 L (PEOPLE
Study). Respir Res. 17(90)2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Collard HR, Ryerson CJ, Corte TJ, Jenkins
G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM,
et al: Acute exacerbation of idiopathic pulmonary fibrosis. An
international working group report. Am J Respir Crit Care Med.
194:265–275. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Goldstraw P, Chansky K, Crowley J,
Rami-Porta R, Asamura H, Eberhardt WEF, Nicholson AG, Groome P,
Mitchell A, Bolejack V, et al: The IASLC lung cancer staging
project: Proposals for revision of the TNM stage groupings in the
forthcoming (eighth) edition of the TNM classification for lung
cancer. J Thorac Oncol. 11:39–51. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Inomata M, Nishioka Y and Azuma A:
Nintedanib: Evidence for its therapeutic potential in idiopathic
pulmonary fibrosis. Core Evid. 10:89–98. 2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hilberg F, Roth GJ, Krssak M, Kautschitsch
S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel
A, Quant J, et al: BIBF 1120: Triple angiokinase inhibitor with
sustained receptor blockade and good antitumor efficacy. Cancer
Res. 68:4774–4782. 2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Saito H, Fukuhara T, Furuya N, Watanabe K,
Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori
K, et al: Erlotinib plus bevacizumab versus erlotinib alone in
patients with EGFR-positive advanced non-squamous non-small cell
lung cancer (NEJ026): Interim analysis of an open-label,
randomised, multicentre, phase 3 trial. Lancet Oncol. 20:625–635.
2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Shimizu R, Fujimoto D, Kato R, Otoshi T,
Kawamura T, Tamai K, Matsumoto T, Nagata K, Otsuka K, Nakagawa A,
et al: The safety and efficacy of paclitaxel and carboplatin with
or without bevacizumab for treating patients with advanced
nonsquamous non-small cell lung cancer with interstitial lung
disease. Cancer Chemother Pharmacol. 74:1159–1166. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Marchioni A, Tonelli R, Ball L, Fantini R,
Castaniere I, Cerri S, Luppi F, Malerba M, Pelosi P and Clini E:
Acute exacerbation of idiopathic pulmonary fibrosis: Lessons
learned from acute respiratory distress syndrome? Crit Care.
22(80)2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Cuesta VMM, Fernández DI, Ibáñez SA,
Francisco GA, Iribarnegaray JM, Hernández-Rubio JC, Mezquida JP,
Luz VP, Hernández RL, de Pablo Gafas A, et al: Antifibrotics and
lung transplantation: A Spanish multicentre case-controlled study.
Respirology. 27:1054–1063. 2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Shan L, Qiao Y, Ma L, Zhang X, Chen C, Xu
X, Li D, Qiu S, Xue X, Yu Y, et al: AuNPs/CNC nanocomposite with a
‘Dual Dispersion’ effect for LDI-TOF MS analysis of intact proteins
in NSCLC serum exosomes. Adv Sci (Weinh).
11(e2307360)2024.PubMed/NCBI View Article : Google Scholar
|
